Thermo Fisher Scooping Up Molecular-Diagnostic Firm
January 19 2021 - 7:40AM
Dow Jones News
By Micah Maidenberg
Thermo Fisher Scientific Inc. said Tuesday it agreed to purchase
a molecular diagnostic company called Mesa Biotech Inc. for about
$450 million in cash.
Mesa has developed a rapid testing platform for infectious
diseases, including Covid-19 and flu strains, and generated roughly
$45 million in revenue last year, Thermo said.
The privately held company's platform will "enable us to
accelerate the availability of reliable and accurate advanced
molecular diagnostics at the point of care," Thermo's operations
chief, Mark Stevenson, said in a statement.
The acquisition is expected to be completed in the current
quarter.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
January 19, 2021 08:25 ET (13:25 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Apr 2024 to May 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From May 2023 to May 2024